Literature DB >> 8674186

Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum.

T Piironen1, J Lövgren, M Karp, R Eerola, A Lundwall, B Dowell, T Lövgren, H Lilja, K Pettersson.   

Abstract

Prostate-specific antigen (PSA) and human prostatic glandular kallikrein (hK2) have 79% identity with the primary structure. When we used recombinant hK2 protein, only 7 of 23 monoclonal anti-PSA IgGs (monoclonal antibodies, MAbs) cross-reacted with hK2, which enabled us to design a novel immunofluorometric MAb-MAb assay for the specific detection of hK2. In the first incubation, an excess of MAb 2H11, which does not cross-react with hK2, is added to prevent both free and complexed PSA from reacting in subsequent immunoreactions. In the second incubation, biotinylated MAb H50, which cross-reacts with hK2 by an epitope overlapping with MAb 2H11, served to bind only hK2 to the microtitration wells coated with streptavidin. In the third step, Eu-labeled MAb H117, which cross-reacts with hK2, detected the immobilized hK2. The hK2 assay was calibrated with recombinant hK2. The detection limit of the assay was 0.1 microgram/L, and the cross-reactivity with recombinant PSA was < or = 0.7%. The concentration of hK2 was measured in serum samples from 334 males with total PSA concentrations ranging from 1 to 3400 microgram/L. Most of the samples (57%) had hK2 concentrations below the detection limit. The proportions of hK2 relative to total PSA were 0-2% in 79%, 2-5% in 14%, 5-10% in 4%, and >10% in 3% of the samples. Gel filtration of 10 serum samples with increased hK2 concentrations showed a single peak of hK2 immunoreactivity with an apparent molecular size of approximately 30 kDa, corresponding to that of recombinant hK2 and free PSA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674186

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

1.  A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.

Authors:  Katharina Braun; Daniel D Sjoberg; Andrew J Vickers; Hans Lilja; Anders S Bjartell
Journal:  Eur Urol       Date:  2015-05-13       Impact factor: 20.096

2.  A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.

Authors:  Melissa Assel; Liisa Sjöblom; Teemu J Murtola; Kirsi Talala; Paula Kujala; Ulf-Håkan Stenman; Kimmo Taari; Anssi Auvinen; Andrew Vickers; Tapio Visakorpi; Teuvo L Tammela; Hans Lilja
Journal:  Eur Urol Focus       Date:  2017-11-11

3.  Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.

Authors:  Melissa J Assel; Hans David Ulmert; R Jeffery Karnes; Stephen A Boorjian; David W Hillman; Andrew J Vickers; George G Klee; Hans Lilja
Journal:  Prostate       Date:  2019-10-11       Impact factor: 4.104

4.  Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.

Authors:  David Ulmert; Andrew J Vickers; Howard I Scher; Charlotte Becker; Peter Iversen; David Frankel; Jens-Kristian Jensen; Tine Kold Olesen; Hans Lilja
Journal:  Clin Chem Lab Med       Date:  2012-11       Impact factor: 3.694

5.  Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling.

Authors:  T Piironen; B O Villoutreix; C Becker; K Hollingsworth; M Vihinen; D Bridon; X Qiu; J Rapp; B Dowell; T Lövgren; K Pettersson; H Lilja
Journal:  Protein Sci       Date:  1998-02       Impact factor: 6.725

Review 6.  Biomarkers in prostate cancer surveillance and screening: past, present, and future.

Authors:  K Clint Cary; Mathew R Cooperberg
Journal:  Ther Adv Urol       Date:  2013-12

Review 7.  [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].

Authors:  A Haese; M Graefen; J Palisaar; E Huland; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

8.  Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.

Authors:  Mesude Bicak; Katharina Lückerath; Teja Kalidindi; Michael E Phelps; Sven-Erik Strand; Michael J Morris; Caius G Radu; Robert Damoiseaux; Mari T Peltola; Norbert Peekhaus; Austin Ho; Darren Veach; Ann-Christin Malmborg Hager; Steven M Larson; Hans Lilja; Michael R McDevitt; Robert J Klein; David Ulmert
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-12       Impact factor: 11.205

9.  Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.

Authors:  Charlotta Sävblom; Christer Halldén; Angel M Cronin; Torbjörn Säll; Caroline Savage; Emily A Vertosick; Robert J Klein; Aleksander Giwercman; Hans Lilja
Journal:  Clin Chem       Date:  2013-11-22       Impact factor: 8.327

Review 10.  Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.

Authors:  Alexander Haese; Markus Graefen; Hartwig Huland; Hans Lilja
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.